Drug Trial Radar · NCT07027527
An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
86
Actual
Start
Jun 4, 2025
Primary completion
Aug 29, 2026
Study completion Dec 2027
Sponsor
- Lead sponsor
- Apogee Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetic (PK) parameters of the combination of APG777 + APG990 in adults with moderate-to-severe atopic dermatitis (AD), in comparison to dupilumab. The duration of the study will be approximately 82 weeks for each participant and will consist of a Screening Period (up to 6 weeks), Treatment Period (Baseline-Week 24), and Follow-up Period (Week 28-Week 76).
Conditions
- Atopic Dermatitis
Interventions
APG777Drug
Subcutaneous (SC) injection
APG990Drug
SC injection
DupilumabDrug
SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 24 weeks
Locations
20 sites in 3 countries. Site status is shown where the registry gives one.
Investigational Site
Darlinghurst, New South Wales, Australia
Investigational Site
Kogarah, New South Wales, Australia
Investigational Site
Westmead, New South Wales, Australia
Investigational Site
Woolloongabba, Queensland, Australia
Investigational Site
Carlton, Victoria, Australia
Investigational Site
East Melbourne, Victoria, Australia
Investigational Site
Mitcham, Victoria, Australia
Investigational Site
Parkville, Victoria, Australia
Investigational Site
Fremantle, Western Australia, Australia
Investigational Site
London, Ontario, Canada
Investigational Site
Peterborough, Ontario, Canada
Investigational Site
Richmond Hill, Ontario, Canada
Investigational Site
Toronto, Ontario, Canada
Investigational Site
Toronto, Ontario, Canada
Investigational Site
Toronto, Ontario, Canada
Investigational Site
Montreal, Quebec, Canada
Investigational Site
Québec, Quebec, Canada
Investigational Site
Sherbrooke, Quebec, Canada
Investigational Site
Auckland, New Zealand
Investigational Site
Hamilton, Waitako, New Zealand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.